DOREMy project

DOREMy project funded by INCa

Within the framework of the ParPedia19 call for projects “Accelerating research in pediatric oncology: aid for pooling, structuring and sharing research data” financed by the INCa in 2019, one of the winning projects is the one led by Prof. Arnaud PETIT for the DOREMy project.

The DOREMy project focuses on the “Harmonized clinical and biological data base for integrated research in the management of paediatric acute myeloid leukaemia”.


Acute myeloid leukaemia in children and adolescents (AML) is a group of rare diseases whose relapse rate remains high (45%) and whose prognosis remains poor (<70%) despite therapeutic advances. The therapeutic protocols LAME89/91, ELAM02, the post-ELAM02 registry and the current Myechild01 protocol have enabled the collection of clinical-biological data since 1989 and the constitution of a tumour library for AML since 2005. In order to better understand the pathophysiology of these diseases, the CONECT AML network of 12 research teams in France was created in 2017 as part of the Programme d’Actions Intégrées de Recherche (PAIR) in pediatric oncology. The various projects include genomic analyses, new experimental models (PDX, cells of the medullary microenvironment, drug testing). The protocol and research data thus generated, the tumour library, the samples dispersed in the research teams are recorded on independent databases, which does not allow an optimal exploitation of these resources.
Goals: to integrate all clinical data into a single database; to integrate the research data from CONECT AML; to adapt these data to the OSIRIS set as well as to the international paediatric AML database, PedAL; to list all leukaemia samples or derived products from the ELAM02 biobank and to create a virtual tumour library of samples stored by the CONECT AML research teams.
Data structuring work must allow interaction with national and international databases. The pooling of data will make it possible to better characterise high-risk subgroups of rare patients; identify new therapeutic targets; reduce the rate of relapse and
improve the survival of pediatric AML; promote data and sample sharing for collaborative work.

More informations :